Latest news articles

Added 2 days ago Drug news

FDA accepts NDA for iclaprim to treat ABSSSI.- Motif Bio plc.

Motif Bio plc has announced that the FDA has accepted for filing the New Drug Application (NDA) for iclaprim, a...

Added 4 days ago Drug news

FDA grants accelerated approval for Galafold treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.--Amicus Therapeutics.

Amicus Therapeutics has announced that the FDA has granted accelerated approval of Galafold (migalastat) 123 mg capsules. Galafold is an...

Added 17 days ago Drug news

CHMP recommends approval of Ilumetri in plaque psoriasis.- Almirall.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...

Search all news articles for Dermatology
 

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

 

Guidelines

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations

The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process.

Added 2 months ago

2018 update of the EULAR recommendations for the management of Behçet’s syndrome

These updated, evidence-based recommendations are intended to help physicians caring for patients with BS.

Added 1 month ago

British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018

The overall objective of the guidelines is to provide up-todate, evidence-based recommendations on the investigation and management of secondary pruritus without underlying skin disorder and generalized pruritus of unknown origin (GPUO) in adults...

Added 5 months ago

Search all guidelines for Dermatology
 

Journal articles

The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch.

To identify itch-related mediators and receptors that are differentially expressed in pruritic skin, we used RNA sequencing to analyze the complete transcriptome in skin from paired itchy, lesional and nonitchy...

Added 1 day ago

Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study.

Objectives: To compare the safety and efficacy of ixekizumab, an IL-17A antagonist, versus the IL-12/23 inhibitor, ustekinumab, through 52 weeks of treatment in the head-to-head trial, IXORA-S.

Added 1 day ago

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Objectives: To compare the risk of serious infections associated with infliximab in patients with chronic plaque psoriasis against a cohort on non-biologic systemic therapies.

Added 1 day ago

Search all journal articles for Dermatology
 

Clinical trials

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (ARROW)

The aim of this study is to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic...

Added 27 days ago

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 1 year ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 1 year ago

Search all clinical trials for Dermatology
 

Blog Posts

Lauren McCracken

EAACI hot topics: Hereditary angioedema (HAE)

Posted 1 month ago

For many the fear of the unknown is a daunting thought, but particularly so for patients with HAE. Left untreated, this disease causes unpredictable recurrent severe swelling, typically of the limbs, face, intestinal tract and airway.

Alex Keen

EULAR 2018 – Biosimilars: the future of rheumatology?

Posted 2 months ago

EULAR's Annual European Congress of Rheumatology aims to encourage innovation and collaboration across all aspects of rheumatology, something that is particularly well illustrated by biologics and their more affordable counterpart, biosimilars. Could they unlock the door to accessible, life-changing treatment for millions more?

Lauren McCracken

EAACI hot topics: Allergen specific immunotherapy (AIT)

Posted 2 months ago

When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.

CME

EAACI 2017: The future of urticaria – advances in CSU research

EAACI 2017: The future of urticaria – advances in CSU research
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics

Chronic Spontaneous Urticaria Case Consults: Changing Paradigms in the Age of Biologics
Accrediting body
Credits available
0
Registration required
1
Subscription fee
FREE

Managing CSU and its comorbidities: from primary to secondary care

Managing CSU and its comorbidities: from primary to secondary care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Dermatology